|
CA3007787C
(en)
|
2010-06-03 |
2020-03-10 |
Pharmacyclics Llc |
The use of inhibitors of bruton's tyrosine kinase (btk)
|
|
PL3409278T3
(pl)
|
2011-07-21 |
2021-02-22 |
Sumitomo Pharma Oncology, Inc. |
Heterocykliczne inhibitory kinazy białkowej
|
|
CA2879570A1
(en)
|
2012-07-24 |
2014-01-30 |
Pharmacyclics, Inc. |
Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
|
|
SI2922875T1
(sl)
|
2012-11-20 |
2017-06-30 |
Sanofi |
Protitelesa anti-CEACAM5 in njihove uporabe
|
|
US10570204B2
(en)
|
2013-09-26 |
2020-02-25 |
The Medical College Of Wisconsin, Inc. |
Methods for treating hematologic cancers
|
|
ES2746805T3
(es)
|
2013-12-12 |
2020-03-06 |
Shanghai hengrui pharmaceutical co ltd |
Anticuerpo de PD-1, fragmento de unión a antígeno del mismo y aplicación médica del mismo
|
|
ES2716685T3
(es)
|
2014-01-24 |
2019-06-14 |
Dana Farber Cancer Inst Inc |
Moléculas de anticuerpo para PD-1 y usos de las mismas
|
|
WO2015119930A1
(en)
|
2014-02-04 |
2015-08-13 |
Pfizer Inc. |
Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer
|
|
TWI777174B
(zh)
|
2014-03-14 |
2022-09-11 |
瑞士商諾華公司 |
針對lag-3之抗體分子及其用途
|
|
EP3119910A4
(en)
|
2014-03-20 |
2018-02-21 |
Pharmacyclics LLC |
Phospholipase c gamma 2 and resistance associated mutations
|
|
RU2016142476A
(ru)
|
2014-03-31 |
2018-05-07 |
Дженентек, Инк. |
Комбинированная терапия, включающая антиангиогенезные агенты и агонисты, связывающие ох40
|
|
AU2015266958A1
(en)
|
2014-05-28 |
2016-12-08 |
Agenus Inc. |
Anti-GITR antibodies and methods of use thereof
|
|
TWI693232B
(zh)
|
2014-06-26 |
2020-05-11 |
美商宏觀基因股份有限公司 |
與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
|
|
EP3191126B1
(en)
|
2014-09-13 |
2020-05-13 |
Novartis AG |
Combination therapies of alk inhibitors
|
|
TWI595006B
(zh)
*
|
2014-12-09 |
2017-08-11 |
禮納特神經系統科學公司 |
抗ｐｄ－１抗體類和使用彼等之方法
|
|
JP6647315B2
(ja)
|
2015-01-09 |
2020-02-14 |
イーチュービクス コーポレイション |
組み合わせ免疫療法のための方法および組成物
|
|
MA41414A
(fr)
*
|
2015-01-28 |
2017-12-05 |
Centre Nat Rech Scient |
Protéines de liaison agonistes d' icos
|
|
US10227408B2
(en)
|
2015-02-19 |
2019-03-12 |
Compugen Ltd. |
Anti-PVRIG antibodies and methods of use
|
|
CN112263677A
(zh)
|
2015-02-26 |
2021-01-26 |
默克专利股份公司 |
用于治疗癌症的pd-1/pd-l1抑制剂
|
|
MA41866A
(fr)
*
|
2015-03-31 |
2018-02-06 |
Massachusetts Gen Hospital |
Molécules à auto-assemblage pour l'administration ciblée de médicaments
|
|
US11149087B2
(en)
*
|
2015-04-20 |
2021-10-19 |
Etubics Corporation |
Methods and compositions for combination immunotherapy
|
|
PL3291679T3
(pl)
|
2015-05-06 |
2022-04-25 |
Snipr Technologies Limited |
Zmiana populacji drobnoustrojowych i modyfikowanie mikrobioty
|
|
PH12017502013B1
(en)
|
2015-05-07 |
2022-07-22 |
Agenus Inc |
Anti-ox40 antibodies and methods of use thereof
|
|
CN111349118B
(zh)
|
2015-05-18 |
2023-08-22 |
住友制药肿瘤公司 |
具有增加的生物利用度的阿伏西地前药
|
|
TWI773646B
(zh)
|
2015-06-08 |
2022-08-11 |
美商宏觀基因股份有限公司 |
結合lag-3的分子和其使用方法
|
|
MY193229A
(en)
|
2015-06-16 |
2022-09-26 |
Merck Patent GmbH |
Pd-l1 antagonist combination treatments
|
|
CN114591433A
(zh)
|
2015-07-13 |
2022-06-07 |
西托姆克斯治疗公司 |
抗pd-1抗体、可活化抗pd-1抗体及其使用方法
|
|
CN116059219A
(zh)
|
2015-07-16 |
2023-05-05 |
比奥克斯塞尔医疗股份有限公司 |
一种使用免疫调节治疗癌症的新颖方法
|
|
HUE055207T2
(hu)
|
2015-07-30 |
2021-11-29 |
Macrogenics Inc |
PD-1 és LAG-3 kötõ molekulák és eljárások azok alkalmazására
|
|
CN114605548A
(zh)
|
2015-09-01 |
2022-06-10 |
艾吉纳斯公司 |
抗-pd-1抗体及其使用方法
|
|
HK1251158A1
(zh)
|
2015-09-29 |
2019-01-25 |
细胞基因公司 |
Pd-1结合蛋白及其使用方法
|
|
SMT202100506T1
(it)
|
2015-10-02 |
2021-11-12 |
Hoffmann La Roche |
Anticorpi bispecifici specifici per pd1 e tim3
|
|
IL257858B
(en)
*
|
2015-10-02 |
2022-09-01 |
Hoffmann La Roche |
Anti-pd1 antibodies and methods of use
|
|
US12030942B2
(en)
|
2015-10-02 |
2024-07-09 |
Les Laboratoires Servier |
Anti-PD-1 antibodies and compositions
|
|
MA43017A
(fr)
|
2015-10-02 |
2018-08-08 |
Hoffmann La Roche |
Anticorps bispécifiques spécifiques d'un récepteur de co-stimulation du tnf
|
|
SMT202200118T1
(it)
|
2015-11-03 |
2022-05-12 |
Janssen Biotech Inc |
Anticorpi che legano specificamente pd-1 e loro usi
|
|
US10858432B2
(en)
|
2015-12-02 |
2020-12-08 |
Stcube, Inc. |
Antibodies specific to glycosylated PD-1 and methods of use thereof
|
|
SG10201912984WA
(en)
|
2015-12-02 |
2020-03-30 |
Agenus Inc |
Antibodies and methods of use thereof
|
|
EA201891178A1
(ru)
|
2015-12-14 |
2019-01-31 |
Макродженикс, Инк. |
Биспецифичные молекулы, обладающие иммунореактивностью в отношении pd-1 и ctla-4, и способы их применения
|
|
EP3416982A1
(en)
|
2016-02-17 |
2018-12-26 |
Novartis AG |
Tgfbeta 2 antibodies
|
|
WO2017165125A1
(en)
*
|
2016-03-24 |
2017-09-28 |
Millennium Pharmaceuticals, Inc. |
Use of a pd-1 antagonist and an anti-ccr2 antibody in the treatment of cancer
|
|
EP3848393A1
(en)
|
2016-05-18 |
2021-07-14 |
Boehringer Ingelheim International GmbH |
Antibody molecules for cancer treatment
|
|
TWI781934B
(zh)
|
2016-05-27 |
2022-11-01 |
美商艾吉納斯公司 |
抗-tim-3抗體及其使用方法
|
|
GB201609811D0
(en)
|
2016-06-05 |
2016-07-20 |
Snipr Technologies Ltd |
Methods, cells, systems, arrays, RNA and kits
|
|
EP3468581A1
(en)
|
2016-06-13 |
2019-04-17 |
Torque Therapeutics, Inc. |
Methods and compositions for promoting immune cell function
|
|
TWI640536B
(zh)
|
2016-06-20 |
2018-11-11 |
克馬伯有限公司 |
抗體
|
|
RU2656181C1
(ru)
|
2016-07-13 |
2018-05-31 |
Закрытое Акционерное Общество "Биокад" |
Анти-pd-1-антитела, способ их получения и способ применения
|
|
JP7373991B2
(ja)
*
|
2016-07-15 |
2023-11-06 |
ビラクタ セラピューティクス，インク． |
免疫療法で使用するためのヒストン脱アセチル化酵素阻害剤
|
|
JP2019528251A
(ja)
*
|
2016-07-20 |
2019-10-10 |
エスティーキューブ，インコーポレイテッド |
グリコシル化ｐｄ−ｌ１に結合する抗体の組合せを使用するがんの処置および治療の方法
|
|
US12158399B2
(en)
*
|
2016-08-05 |
2024-12-03 |
Duke University |
CaMKK2 inhibitor compositions and methods of using the same
|
|
WO2018027524A1
(en)
|
2016-08-09 |
2018-02-15 |
Innovent Biologics (Suzhou) Co., Ltd. |
Pd-1 antibody formulation
|
|
CN112274637A
(zh)
|
2016-08-17 |
2021-01-29 |
康姆普根有限公司 |
抗tigit抗体、抗pvrig抗体及其组合
|
|
WO2018039629A2
(en)
|
2016-08-25 |
2018-03-01 |
Northwestern University |
Micellar spherical nucleic acids from thermoresponsive, traceless templates
|
|
ES2977137T3
(es)
*
|
2016-09-16 |
2024-08-19 |
Shanghai Henlius Biotech Inc |
Anticuerpos anti-PD-1
|
|
AU2017326751B2
(en)
*
|
2016-09-16 |
2024-10-10 |
Bionomics Limited |
Antibody and checkpoint inhibitor combination therapy
|
|
AU2017329024A1
(en)
|
2016-09-19 |
2019-03-21 |
Celgene Corporation |
Methods of treating immune disorders using pd-1 binding proteins
|
|
WO2018053401A1
(en)
|
2016-09-19 |
2018-03-22 |
Celgene Corporation |
Methods of treating vitiligo using pd-1 binding proteins
|
|
LT3515938T
(lt)
|
2016-09-21 |
2025-05-12 |
Cstone Pharmaceuticals |
Monokloniniai antikūnai prieš programuojamą mirtį 1 (pd-1)
|
|
AU2017339856B2
(en)
|
2016-10-06 |
2024-09-05 |
Merck Patent Gmbh |
Dosing regimen of avelumab for the treatment of cancer
|
|
TW202436356A
(zh)
|
2016-10-11 |
2024-09-16 |
美商艾吉納斯公司 |
抗ｌａｇ－３抗體及其使用方法
|
|
EP3538152A4
(en)
|
2016-11-09 |
2020-09-30 |
Agenus Inc. |
ANTI-OX40 ANTIBODIES, ANTI-GITR ANTIBODIES, AND PROCESSES FOR USE
|
|
US11279694B2
(en)
|
2016-11-18 |
2022-03-22 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Alvocidib prodrugs and their use as protein kinase inhibitors
|
|
EP3541841B1
(en)
*
|
2016-11-18 |
2024-09-11 |
Les Laboratoires Servier |
Anti-pd-1 antibodies and compositions
|
|
CN118634323A
(zh)
|
2016-12-07 |
2024-09-13 |
艾吉纳斯公司 |
抗体和其使用方法
|
|
WO2018112407A1
(en)
*
|
2016-12-15 |
2018-06-21 |
Duke University |
Antibodies and methods for depleting regulatory b10 cells and use in combination with immune checkpoint inhibitors
|
|
WO2018119474A2
(en)
*
|
2016-12-23 |
2018-06-28 |
Remd Biotherapeutics, Inc. |
Immunotherapy using antibodies that bind programmed death 1 (pd-1)
|
|
CN113480530A
(zh)
|
2016-12-26 |
2021-10-08 |
阿里根公司 |
芳香烃受体调节剂
|
|
WO2018134784A1
(en)
|
2017-01-20 |
2018-07-26 |
Novartis Ag |
Combination therapy for the treatment of cancer
|
|
WO2018133842A1
(zh)
|
2017-01-20 |
2018-07-26 |
大有华夏生物医药集团有限公司 |
人程序性死亡受体pd-1的单克隆抗体及其片段
|
|
TW202506185A
(zh)
|
2017-01-20 |
2025-02-16 |
法商賽諾菲公司 |
抗TGF-β抗體及其用途
|
|
EA201991729A1
(ru)
|
2017-01-20 |
2019-12-30 |
Санофи |
Антитела к tgf-бета и их применение
|
|
AR110755A1
(es)
|
2017-01-20 |
2019-05-02 |
Genzyme Corp |
Anticuerpos dirigidos a hueso
|
|
PT3579874T
(pt)
|
2017-02-10 |
2021-10-07 |
Novartis Ag |
1-(4-amino-5-bromo-6-(1h-pirazol-1-il)pirimidin-2-il)-1hpirazol- 4-ol e sua utilização no tratamento de cancro
|
|
EP3583113B1
(en)
|
2017-02-17 |
2025-08-20 |
George Todaro |
Immunotherapeutic combinaton for the treatment of tgf alpha-expressing lung cancer or tgf alpha expressing melanoma
|
|
SG11201907753TA
(en)
|
2017-02-24 |
2019-09-27 |
Macrogenics Inc |
Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
|
|
WO2018160540A1
(en)
|
2017-02-28 |
2018-09-07 |
Sanofi |
Therapeutic rna
|
|
EP3589652B1
(en)
*
|
2017-03-04 |
2024-12-25 |
Xiangtan Tenghua Bioscience |
Recombinant antibodies to programmed death 1 (pd-1) and uses therefor
|
|
MX2019010555A
(es)
*
|
2017-03-27 |
2019-12-11 |
Univ Hokkaido Nat Univ Corp |
Anticuerpo anti-pd-l1 para detectar pd-l1.
|
|
CA3055984A1
(en)
*
|
2017-03-29 |
2018-10-04 |
Celgene Corporation |
Formulations comprising pd-1 binding proteins and methods of making thereof
|
|
PL3431105T3
(pl)
|
2017-03-29 |
2020-11-02 |
Shionogi & Co., Ltd. |
Kompozycja lecznicza do leczenia raka
|
|
KR20190121816A
(ko)
|
2017-04-03 |
2019-10-28 |
에프. 호프만-라 로슈 아게 |
항-pd-1 항체와 돌연변이 il-2 또는 il-15의 면역접합체
|
|
US20200248183A1
(en)
*
|
2017-04-03 |
2020-08-06 |
Subbarao Nallagatla |
Tlr9-targeted spherical nucleic acids having potent antitumor activity
|
|
PL3606955T3
(pl)
|
2017-04-05 |
2025-02-24 |
F. Hoffmann-La Roche Ag |
Przeciwciała dwuswoiste swoiście wiążące się z PD1 i LAG3
|
|
CA3185303A1
(en)
|
2017-04-05 |
2018-10-11 |
Symphogen A/S |
Combination therapies targeting pd-a, tim-3, and lag-3
|
|
JOP20190222A1
(ar)
*
|
2017-04-11 |
2019-09-24 |
Zymeworks Inc |
الأجسام المضادة ثنائية النوعية المضادة لـ pd-l1 والمضادة لـ tim-3
|
|
WO2018201090A1
(en)
|
2017-04-28 |
2018-11-01 |
Exicure, Inc. |
Synthesis of spherical nucleic acids using lipophilic moieties
|
|
AR111651A1
(es)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
|
US11433131B2
(en)
|
2017-05-11 |
2022-09-06 |
Northwestern University |
Adoptive cell therapy using spherical nucleic acids (SNAs)
|
|
AR111760A1
(es)
|
2017-05-19 |
2019-08-14 |
Novartis Ag |
Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral
|
|
JOP20190279A1
(ar)
|
2017-05-31 |
2019-11-28 |
Novartis Ag |
الصور البلورية من 5-برومو -2، 6-داي (1h-بيرازول -1-يل) بيريميدين -4- أمين وأملاح جديدة
|
|
AU2018282094B2
(en)
*
|
2017-06-05 |
2024-06-27 |
Janssen Biotech, Inc. |
Antibodies that specifically bind PD-1 and methods of use
|
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
|
KR20200019865A
(ko)
|
2017-06-22 |
2020-02-25 |
노파르티스 아게 |
암 치료에 사용하기 위한 il-1베타 결합 항체
|
|
WO2018237173A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
CN110785187B
(zh)
|
2017-06-22 |
2024-04-05 |
诺华股份有限公司 |
针对cd73的抗体分子及其用途
|
|
WO2018235056A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
Il-1beta binding antibodies for use in treating cancer
|
|
US20200223924A1
(en)
|
2017-06-27 |
2020-07-16 |
Novartis Ag |
Dosage regimens for anti-tim-3 antibodies and uses thereof
|
|
EP3421494A1
(en)
|
2017-06-29 |
2019-01-02 |
Sanofi |
Use of isatuximab in combination with an anti-pd-1 antibody
|
|
CA3069363A1
(en)
|
2017-07-11 |
2019-01-17 |
Pfizer Inc. |
Immunogenic compositions comprising cea muc1 and tert
|
|
CN111163798A
(zh)
|
2017-07-20 |
2020-05-15 |
诺华股份有限公司 |
用于抗lag-3抗体的给药方案及其用途
|
|
WO2019032663A1
(en)
*
|
2017-08-09 |
2019-02-14 |
Orionis Biosciences Inc. |
PD-1 AND PD-L1 BINDING AGENTS
|
|
US11021540B2
(en)
*
|
2017-09-07 |
2021-06-01 |
Augusta University Research Institute, Inc. |
Antibodies to programmed cell death protein 1
|
|
WO2019055579A1
(en)
|
2017-09-12 |
2019-03-21 |
Tolero Pharmaceuticals, Inc. |
TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR
|
|
CN111225685A
(zh)
|
2017-10-13 |
2020-06-02 |
默克专利股份有限公司 |
Parp抑制剂和pd-1轴结合拮抗剂的组合
|
|
ES2938652T3
(es)
*
|
2017-10-18 |
2023-04-13 |
Forty Seven Inc |
Tratamiento del cáncer de ovario con anti-CD47 y anti-PD-L1
|
|
US11802153B2
(en)
|
2017-10-18 |
2023-10-31 |
Forty Seven, Inc. |
Anti-CD47 agent-based ovarian cancer therapy
|
|
WO2019081983A1
(en)
|
2017-10-25 |
2019-05-02 |
Novartis Ag |
CD32B TARGETING ANTIBODIES AND METHODS OF USE
|
|
CN111278443A
(zh)
*
|
2017-11-08 |
2020-06-12 |
丹娜法伯癌症研究院 |
使用rhoa显性负型治疗癌症的组合物和方法
|
|
WO2019094265A1
(en)
*
|
2017-11-10 |
2019-05-16 |
Armo Biosciences, Inc. |
Pd1 polypeptide binding molecules
|
|
EP3710057A1
(en)
|
2017-11-14 |
2020-09-23 |
Pfizer Inc |
Ezh2 inhibitor combination therapies
|
|
MX2020004756A
(es)
|
2017-11-16 |
2020-08-20 |
Novartis Ag |
Terapias de combinacion.
|
|
CN109793892B
(zh)
*
|
2017-11-16 |
2022-07-26 |
江苏恒瑞医药股份有限公司 |
一种抗pd-1抗体在制备治疗食管癌的药物中的用途
|
|
JP2021503498A
(ja)
|
2017-11-20 |
2021-02-12 |
アリアジェン，インコーポレイテッド |
アリール炭化水素受容体（ａｈｒ）調節剤としてのインドール化合物
|
|
CA3083949A1
(en)
|
2017-11-30 |
2020-06-06 |
Novartis Ag |
Bcma-targeting chimeric antigen receptor, and uses thereof
|
|
WO2019109238A1
(en)
*
|
2017-12-05 |
2019-06-13 |
Lyvgen Biopharma Co., Ltd. |
Anti-cd137 antibodies and uses thereof
|
|
TW201938165A
(zh)
|
2017-12-18 |
2019-10-01 |
美商輝瑞股份有限公司 |
治療癌症的方法及組合療法
|
|
CN112218651A
(zh)
|
2018-01-08 |
2021-01-12 |
诺华公司 |
用于与嵌合抗原受体疗法组合的免疫增强rna
|
|
US12398209B2
(en)
|
2018-01-22 |
2025-08-26 |
Janssen Biotech, Inc. |
Methods of treating cancers with antagonistic anti-PD-1 antibodies
|
|
US20210038659A1
(en)
|
2018-01-31 |
2021-02-11 |
Novartis Ag |
Combination therapy using a chimeric antigen receptor
|
|
EP3752203A1
(en)
|
2018-02-13 |
2020-12-23 |
Novartis AG |
Chimeric antigen receptor therapy in combination with il-15r and il15
|
|
JP7110369B2
(ja)
*
|
2018-02-23 |
2022-08-01 |
ユーキュア・（ベイジン）・バイオファーマ・カンパニー・リミテッド |
抗ｐｄ－１抗体及びその用途
|
|
EP3759129A1
(en)
|
2018-02-28 |
2021-01-06 |
Pfizer Inc |
Il-15 variants and uses thereof
|
|
MY199140A
(en)
|
2018-02-28 |
2023-10-17 |
Ap Biosciences Inc |
Bifunctional proteins combining checkpoint blockade for targeted therapy
|
|
IL277095B2
(en)
*
|
2018-03-07 |
2025-10-01 |
Pfizer |
Preparations containing anti-PD-1 antibody
|
|
CN108434452A
(zh)
*
|
2018-03-13 |
2018-08-24 |
安徽瀚海博兴生物技术有限公司 |
一种将pd-1抗体和jmjd6联合用于制备抗癌药物的应用
|
|
US10760075B2
(en)
|
2018-04-30 |
2020-09-01 |
Snipr Biome Aps |
Treating and preventing microbial infections
|
|
US20210147547A1
(en)
|
2018-04-13 |
2021-05-20 |
Novartis Ag |
Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
|
|
JP7054573B2
(ja)
|
2018-04-15 |
2022-04-14 |
イムヴィラ・カンパニー・リミテッド |
Ｐｄ－１結合抗体及びその用途
|
|
BR112020022145A2
(pt)
|
2018-05-04 |
2021-01-26 |
Merck Patent Gmbh |
inibição combinada de pd-1/pd-l1, tgfbeta e dna-pk para o tratamento de câncer
|
|
EP3796983A2
(en)
|
2018-05-23 |
2021-03-31 |
Pfizer Inc. |
Antibodies specific for gucy2c and uses thereof
|
|
PL3797121T3
(pl)
|
2018-05-23 |
2024-09-23 |
Pfizer Inc. |
Przeciwciała swoiste dla CD3 i ich zastosowania
|
|
TWI869346B
(zh)
|
2018-05-30 |
2025-01-11 |
瑞士商諾華公司 |
Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
|
|
WO2019232244A2
(en)
|
2018-05-31 |
2019-12-05 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
KR20250151605A
(ko)
|
2018-06-01 |
2025-10-21 |
노파르티스 아게 |
Bcma에 대한 결합 분자 및 이의 용도
|
|
JP7403479B2
(ja)
*
|
2018-06-03 |
2023-12-22 |
ランカプ バイオ ベータ リミテッド |
Ｃｅａｃａｍ５およびｃｄ４７に対する二重特異性抗体
|
|
CN120714023A
(zh)
|
2018-06-20 |
2025-09-30 |
因赛特公司 |
抗pd-1抗体及其用途
|
|
BR122022012697B1
(pt)
|
2018-07-10 |
2023-04-04 |
Novartis Ag |
Usos de derivados de 3-(5-hidróxi-1-oxoisoindolin-2-il)piperidina-2,6- diona, e kit
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
EP3823991A4
(en)
*
|
2018-07-19 |
2022-08-03 |
Tayu Huaxia Biotech Medical Group Co., Ltd. |
ANTI-PD-1 ANTIBODIES, DOSAGE FORMS AND USES THEREOF
|
|
WO2020021465A1
(en)
|
2018-07-25 |
2020-01-30 |
Advanced Accelerator Applications (Italy) S.R.L. |
Method of treatment of neuroendocrine tumors
|
|
TWI803682B
(zh)
|
2018-08-20 |
2023-06-01 |
美商輝瑞股份有限公司 |
抗－ｇｄｆ１５抗體、組成物及使用方法
|
|
TW202023625A
(zh)
|
2018-08-23 |
2020-07-01 |
美商西雅圖遺傳學公司 |
抗tigit抗體
|
|
WO2020041655A1
(en)
|
2018-08-24 |
2020-02-27 |
Sanofi |
Therapeutic rna for solid tumor cancers
|
|
WO2020044252A1
(en)
|
2018-08-31 |
2020-03-05 |
Novartis Ag |
Dosage regimes for anti-m-csf antibodies and uses thereof
|
|
AU2019336197A1
(en)
|
2018-09-07 |
2021-02-18 |
Pfizer Inc. |
Anti-avb8 antibodies and compositions and uses thereof
|
|
WO2020049534A1
(en)
|
2018-09-07 |
2020-03-12 |
Novartis Ag |
Sting agonist and combination therapy thereof for the treatment of cancer
|
|
BR112021004935A2
(pt)
|
2018-09-26 |
2021-06-01 |
Merck Patent Gmbh |
combinação de antagonista de pd-1, inibidor de atr e agente de platinação para tratamento de câncer
|
|
US12331320B2
(en)
|
2018-10-10 |
2025-06-17 |
The Research Foundation For The State University Of New York |
Genome edited cancer cell vaccines
|
|
WO2020079581A1
(en)
|
2018-10-16 |
2020-04-23 |
Novartis Ag |
Tumor mutation burden alone or in combination with immune markers as biomarkers for predicting response to targeted therapy
|
|
US20230053449A1
(en)
|
2018-10-31 |
2023-02-23 |
Novartis Ag |
Dc-sign antibody drug conjugates
|
|
AU2019372436A1
(en)
*
|
2018-11-01 |
2021-05-20 |
Merck Patent Gmbh |
Methods of administering anti-TIM-3 antibodies
|
|
WO2020095184A1
(en)
|
2018-11-05 |
2020-05-14 |
Pfizer Inc. |
Combinations for treating cancer
|
|
WO2020095183A1
(en)
|
2018-11-05 |
2020-05-14 |
Pfizer Inc. |
Combination for treating cancer
|
|
WO2020106695A1
(en)
|
2018-11-19 |
2020-05-28 |
Ariagen, Inc. |
Methods of treating cancer
|
|
CA3116564A1
(en)
|
2018-11-19 |
2020-05-28 |
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. |
Anti-pd-1 antibodies and uses thereof
|
|
MX2021006544A
(es)
|
2018-12-04 |
2021-07-07 |
Sumitomo Pharma Oncology Inc |
Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer.
|
|
EP3666905A1
(en)
|
2018-12-11 |
2020-06-17 |
Sanofi |
E. coli positive for pks island as marker of positive response to anti-pd1 therapy in colorectal cancer
|
|
JP7196311B2
(ja)
*
|
2018-12-12 |
2022-12-26 |
ウーシー バイオロジクス アイルランド リミテッド |
抗ｔｉｍ－３抗体とその利用
|
|
MX2021007392A
(es)
|
2018-12-20 |
2021-08-24 |
Novartis Ag |
Regimen de dosificacion y combinacion farmaceutica que comprende derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona.
|
|
CN111349162A
(zh)
|
2018-12-21 |
2020-06-30 |
神州细胞工程有限公司 |
人源化抗pd-1抗体及其用途
|
|
EP3897613A1
(en)
|
2018-12-21 |
2021-10-27 |
Novartis AG |
Use of il-1beta binding antibodies
|
|
US20220056123A1
(en)
|
2018-12-21 |
2022-02-24 |
Novartis Ag |
Use of il-1beta binding antibodies
|
|
MX2021007271A
(es)
|
2018-12-21 |
2021-07-15 |
Onxeo |
Nuevas moleculas de acido nucleico conjugado y sus usos.
|
|
WO2020128637A1
(en)
|
2018-12-21 |
2020-06-25 |
Novartis Ag |
Use of il-1 binding antibodies in the treatment of a msi-h cancer
|
|
WO2020128893A1
(en)
|
2018-12-21 |
2020-06-25 |
Pfizer Inc. |
Combination treatments of cancer comprising a tlr agonist
|
|
AU2019406840A1
(en)
|
2018-12-21 |
2021-06-03 |
Novartis Ag |
Use of IL-1 beta antibodies in the treatment or prevention of myelodysplastic syndrome
|
|
WO2020135415A1
(zh)
*
|
2018-12-24 |
2020-07-02 |
正大天晴药业集团股份有限公司 |
抗pd-l1单克隆抗体治疗癌症的用途
|
|
KR20210121046A
(ko)
*
|
2018-12-27 |
2021-10-07 |
기가젠, 인코포레이티드 |
항-pd-1 결합 단백질 및 이의 사용 방법
|
|
WO2020148612A1
(en)
|
2019-01-14 |
2020-07-23 |
Ignite Immunotherapy, Inc. |
Recombinant vaccinia virus and methods of use thereof
|
|
TWI850316B
(zh)
|
2019-01-21 |
2024-08-01 |
法商賽諾菲公司 |
用於晚期實性瘤癌症之治療性rna及抗pd1抗體
|
|
KR20210126652A
(ko)
|
2019-02-12 |
2021-10-20 |
노파르티스 아게 |
Tno155 및 pd-1 억제제를 포함하는 약제학적 조합물
|
|
NZ778055A
(en)
|
2019-02-12 |
2025-11-28 |
Sumitomo Pharma America Inc |
Formulations comprising heterocyclic protein kinase inhibitors
|
|
JP2022520220A
(ja)
|
2019-02-14 |
2022-03-29 |
イグナイト イミュノセラピー インク |
組換えワクシニアウイルスおよびその使用方法
|
|
BR112021015783A2
(pt)
|
2019-02-15 |
2021-10-05 |
Novartis Ag |
Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina-2,6-diona e usos dos mesmos
|
|
WO2020165834A1
(en)
|
2019-02-15 |
2020-08-20 |
Novartis Ag |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
JP2022525149A
(ja)
|
2019-03-20 |
2022-05-11 |
スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド |
ベネトクラクスが失敗した急性骨髄性白血病（ａｍｌ）の処置
|
|
WO2020198077A1
(en)
|
2019-03-22 |
2020-10-01 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Compositions comprising pkm2 modulators and methods of treatment using the same
|
|
US12331120B2
(en)
|
2019-04-11 |
2025-06-17 |
Scripps Korea Antibody Institute |
Antibodies against programmed death-ligand 1 and uses thereof
|
|
CN113906021A
(zh)
|
2019-04-15 |
2022-01-07 |
阿里根公司 |
手性吲哚化合物及其用途
|
|
US20220213193A1
(en)
|
2019-05-06 |
2022-07-07 |
Brown University |
Bispecific antibodies against chi3l1 and pd1 with enhanced t cell-mediated cytotoxic effects on tumor cells
|
|
CN111973739B
(zh)
*
|
2019-05-23 |
2024-02-13 |
正大天晴药业集团股份有限公司 |
抗pd-l1单克隆抗体治疗癌症的用途
|
|
CN113874036A
(zh)
|
2019-05-24 |
2021-12-31 |
辉瑞公司 |
使用cdk抑制剂的联合治疗
|
|
CN114302878A
(zh)
|
2019-07-03 |
2022-04-08 |
大日本住友制药肿瘤公司 |
酪氨酸激酶非受体1(tnk1)抑制剂及其用途
|
|
MX2021015501A
(es)
*
|
2019-07-03 |
2022-04-20 |
Oxford Biotherapeutics Ltd |
Anticuerpos y metodos de uso.
|
|
EP3998081A4
(en)
|
2019-07-05 |
2023-07-12 |
Ono Pharmaceutical Co., Ltd. |
TREATMENT OF BLOOD CANCER WITH PD-1/CD3 DUAL SPECIFICITY PROTEIN
|
|
WO2021005546A1
(en)
|
2019-07-09 |
2021-01-14 |
Cadila Healthcare Limited |
Antibodies to human programmed death receptor pd-1
|
|
AU2020315163B2
(en)
*
|
2019-07-17 |
2025-11-20 |
Bioinvent International Ab |
Antibody combinations for treatment of cancer in specific patients
|
|
WO2021024020A1
(en)
|
2019-08-06 |
2021-02-11 |
Astellas Pharma Inc. |
Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
|
|
JP7771749B2
(ja)
|
2019-08-08 |
2025-11-18 |
小野薬品工業株式会社 |
二重特異性タンパク質
|
|
TW202124446A
(zh)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
與ｅｎｔｐｄ２抗體之組合療法
|
|
WO2021053559A1
(en)
|
2019-09-18 |
2021-03-25 |
Novartis Ag |
Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
|
|
WO2021055994A1
(en)
|
2019-09-22 |
2021-03-25 |
Bristol-Myers Squibb Company |
Quantitative spatial profiling for lag-3 antagonist therapy
|
|
MX2022003633A
(es)
|
2019-09-25 |
2022-04-19 |
Pfizer |
Moduladores poliheterociclicos de sting (estimulador de genes de interferon).
|
|
AU2020370832A1
(en)
|
2019-10-21 |
2022-05-19 |
Novartis Ag |
TIM-3 inhibitors and uses thereof
|
|
BR112022007376A2
(pt)
|
2019-10-21 |
2022-07-05 |
Novartis Ag |
Terapias de combinação com venetoclax e inibidores de tim-3
|
|
CN115942973A
(zh)
|
2019-11-08 |
2023-04-07 |
百时美施贵宝公司 |
用于黑色素瘤的lag-3拮抗剂疗法
|
|
US20230000864A1
(en)
|
2019-11-22 |
2023-01-05 |
Sumitomo Pharma Oncology, Inc. |
Solid dose pharmaceutical composition
|
|
CA3163805A1
(en)
|
2019-12-12 |
2021-06-17 |
Ignite Immunotherapy, Inc. |
Variant oncolytic vaccinia virus and methods of use thereof
|
|
JP7369297B2
(ja)
|
2019-12-17 |
2023-10-25 |
ファイザー・インク |
Ｃｄ４７、ｐｄ－ｌ１に特異的な抗体、およびその使用
|
|
US20230043985A1
(en)
|
2019-12-18 |
2023-02-09 |
Pfizer Inc. |
Once daily cancer treatment regimen with a prmt5 inhibitor
|
|
TW202135859A
(zh)
|
2019-12-20 |
2021-10-01 |
瑞士商諾華公司 |
組合療法
|
|
WO2021140435A1
(en)
|
2020-01-09 |
2021-07-15 |
Pfizer Inc. |
Recombinant vaccinia virus
|
|
MX2022008763A
(es)
|
2020-01-17 |
2022-07-27 |
Novartis Ag |
Combinacion que comprende un inhibidor de tim-3 y un agente hipometilante para usarse en el tratamiento del sindrome mielodisplasico o leucemia mielomonocitica cronica.
|
|
AU2021225491A1
(en)
|
2020-02-28 |
2022-10-20 |
Novartis Ag |
A triple pharmaceutical combination comprising dabrafenib, an Erk inhibitor and a RAF inhibitor
|
|
WO2021176330A1
(en)
|
2020-03-03 |
2021-09-10 |
Array Biopharma Inc. |
Methods to treat cancer using (r)-n-(3-fluoro-4-((3-((1-hydroxypropan-2-yl)amino)-1h-pyrazolo[3,4-b]pyridin-4-yl)oxy)phenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide
|
|
WO2021181233A2
(en)
|
2020-03-09 |
2021-09-16 |
Pfizer Inc. |
Fusion proteins and uses thereof
|
|
AU2021260982B2
(en)
|
2020-04-21 |
2024-03-28 |
Novartis Ag |
Dosing regimen for treating a disease modulated by CSF-1R
|
|
KR20230008197A
(ko)
|
2020-05-13 |
2023-01-13 |
화이자 인코포레이티드 |
암을 치료하기 위한 방법, 요법 및 용도
|
|
PH12022553181A1
(en)
*
|
2020-05-26 |
2024-03-04 |
Boehringer Ingelheim Int |
Anti-pd-1 antibodies
|
|
CN111607565A
(zh)
*
|
2020-06-04 |
2020-09-01 |
河南大学 |
一种北平顶猴t细胞的体外扩增方法
|
|
TW202214857A
(zh)
|
2020-06-19 |
2022-04-16 |
法商昂席歐公司 |
新型結合核酸分子及其用途
|
|
WO2021260528A1
(en)
|
2020-06-23 |
2021-12-30 |
Novartis Ag |
Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
US20230250173A1
(en)
|
2020-07-01 |
2023-08-10 |
Pfizer Inc. |
Biomarkers for pd-1 axis binding antagonist therapy
|
|
US20250262293A1
(en)
|
2020-07-07 |
2025-08-21 |
BioNTech SE |
Therapeutic rna for hpv-positive cancer
|
|
WO2022009157A1
(en)
|
2020-07-10 |
2022-01-13 |
Novartis Ag |
Lhc165 and spartalizumab combinations for treating solid tumors
|
|
US20220033784A1
(en)
|
2020-07-14 |
2022-02-03 |
Pfizer Inc. |
Recombinant vaccinia virus
|
|
MX2023000662A
(es)
|
2020-07-17 |
2023-02-27 |
Pfizer |
Anticuerpos terapeuticos y sus usos.
|
|
JP7819176B2
(ja)
|
2020-08-03 |
2026-02-24 |
ノバルティス アーゲー |
ヘテロアリール置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
|
|
EP4204095A1
(en)
|
2020-08-28 |
2023-07-05 |
Bristol-Myers Squibb Company |
Lag-3 antagonist therapy for hepatocellular carcinoma
|
|
US20230338587A1
(en)
|
2020-08-31 |
2023-10-26 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
|
WO2022043557A1
(en)
|
2020-08-31 |
2022-03-03 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
|
IL300884A
(en)
|
2020-09-14 |
2023-04-01 |
Pfizer |
Treatment methods and uses for cancer treatment
|
|
AU2021364837A1
(en)
|
2020-10-23 |
2023-05-25 |
Bristol-Myers Squibb Company |
Lag-3 antagonist therapy for lung cancer
|
|
IL302569A
(en)
|
2020-11-06 |
2023-07-01 |
Novartis Ag |
Cd19 binding molecules and uses thereof
|
|
IL302731A
(en)
|
2020-11-10 |
2023-07-01 |
Sanofi Sa |
Formulation of an antibody-drug conjugate for CEACAM5
|
|
US20220168293A1
(en)
|
2020-12-02 |
2022-06-02 |
Pfizer Inc. |
Time to resolution of axitinib-related adverse events
|
|
TW202237119A
(zh)
|
2020-12-10 |
2022-10-01 |
美商住友製藥腫瘤公司 |
Ａｌｋ﹘５抑制劑和彼之用途
|
|
WO2022130206A1
(en)
|
2020-12-16 |
2022-06-23 |
Pfizer Inc. |
TGFβr1 INHIBITOR COMBINATION THERAPIES
|
|
CN116635064A
(zh)
|
2020-12-18 |
2023-08-22 |
世纪治疗股份有限公司 |
具有适应性受体特异性的嵌合抗原受体系统
|
|
WO2022135666A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Treatment schedule for cytokine proteins
|
|
WO2022135667A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Therapeutic rna for treating cancer
|
|
TW202245808A
(zh)
|
2020-12-21 |
2022-12-01 |
德商拜恩迪克公司 |
用於治療癌症之治療性ｒｎａ
|
|
WO2022153161A1
(en)
|
2021-01-14 |
2022-07-21 |
Pfizer Inc. |
Treatment of cancer using a prmt5 inhibitor
|
|
JP2024505049A
(ja)
|
2021-01-29 |
2024-02-02 |
ノバルティス アーゲー |
抗ｃｄ７３及び抗ｅｎｔｐｄ２抗体のための投与方式並びにその使用
|
|
US11964978B2
(en)
|
2021-03-18 |
2024-04-23 |
Pfizer Inc. |
Modulators of STING (stimulator of interferon genes)
|
|
EP4308935A1
(en)
|
2021-03-18 |
2024-01-24 |
Novartis AG |
Biomarkers for cancer and methods of use thereof
|
|
TW202304506A
(zh)
|
2021-03-25 |
2023-02-01 |
日商安斯泰來製藥公司 |
涉及抗claudin 18.2抗體的組合治療以治療癌症
|
|
US20240181052A1
(en)
|
2021-03-29 |
2024-06-06 |
Juno Therapeutics, Inc. |
Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
US12037346B2
(en)
|
2021-04-13 |
2024-07-16 |
Nuvalent, Inc. |
Amino-substituted heteroaryls for treating cancers with EGFR mutations
|
|
US20240228659A1
(en)
|
2021-04-14 |
2024-07-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method to improve nk cells cytotoxicity
|
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
|
CN117337300A
(zh)
*
|
2021-05-21 |
2024-01-02 |
百奥泰生物制药股份有限公司 |
抗pd-1抗体的应用
|
|
GB202107994D0
(en)
|
2021-06-04 |
2021-07-21 |
Kymab Ltd |
Treatment of cancer
|
|
KR20240022608A
(ko)
|
2021-06-18 |
2024-02-20 |
젠자임 코포레이션 |
항-tgf-베타 항체 제형 및 이의 용도
|
|
WO2023274275A1
(zh)
*
|
2021-07-01 |
2023-01-05 |
天津立博美华基因科技有限责任公司 |
药物组合及其用途
|
|
MX2024000674A
(es)
|
2021-07-13 |
2024-02-07 |
BioNTech SE |
Agentes de union multiespecificos contra cd40 y cd137 en terapia de combinacion.
|
|
CA3224853A1
(en)
|
2021-07-14 |
2023-01-19 |
Gautham GAMPA |
Anti-c-c motif chemokine receptor 8 (ccr8) antibodies and methods of use
|
|
WO2023051926A1
(en)
|
2021-09-30 |
2023-04-06 |
BioNTech SE |
Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists
|
|
TW202327595A
(zh)
|
2021-10-05 |
2023-07-16 |
美商輝瑞大藥廠 |
用於治療癌症之氮雜內醯胺化合物的組合
|
|
TW202333802A
(zh)
|
2021-10-11 |
2023-09-01 |
德商拜恩迪克公司 |
用於肺癌之治療性rna(二)
|
|
CN118176214A
(zh)
|
2021-10-29 |
2024-06-11 |
百时美施贵宝公司 |
血液癌症的lag-3拮抗剂疗法
|
|
JP2024541933A
(ja)
|
2021-11-02 |
2024-11-13 |
ファイザー・インク |
抗ｇｄｆ１５抗体を使用してミトコンドリア筋症を処置する方法
|
|
WO2023079428A1
(en)
|
2021-11-03 |
2023-05-11 |
Pfizer Inc. |
Combination therapies using tlr7/8 agonist
|
|
WO2023083439A1
(en)
|
2021-11-09 |
2023-05-19 |
BioNTech SE |
Tlr7 agonist and combinations for cancer treatment
|
|
MX2024005722A
(es)
|
2021-11-12 |
2024-05-28 |
Novartis Ag |
Terapia de combinacion para el tratamiento del cancer de pulmon.
|
|
US20240294926A1
(en)
|
2021-12-16 |
2024-09-05 |
Valerio Therapeutics |
New conjugated nucleic acid molecules and their uses
|
|
MX2024008831A
(es)
|
2022-01-26 |
2024-07-25 |
Bristol Myers Squibb Co |
Terapia combinada para carcinoma hepatocelular.
|
|
WO2023147470A2
(en)
|
2022-01-28 |
2023-08-03 |
Georgiamune Inc. |
Antibodies to programmed cell death protein 1 that are pd-1 agonists
|
|
MX2024010310A
(es)
|
2022-02-25 |
2024-08-28 |
Bristol Myers Squibb Co |
Terapia de combinacion para carcinoma colorrectal.
|
|
AU2023228391A1
(en)
|
2022-03-03 |
2024-09-19 |
Pfizer Inc. |
Multispecific antibodies binding to il-4, il-13 and/or tslp and uses thereof
|
|
WO2023214325A1
(en)
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
|
|
WO2023218320A1
(en)
|
2022-05-11 |
2023-11-16 |
Pfizer Inc. |
Anti-lymphotoxin beta receptor antibodies and methods of use thereof
|
|
EP4531916A1
(en)
|
2022-06-02 |
2025-04-09 |
Bristol-Myers Squibb Company |
Antibody compositions and methods of use thereof
|
|
CA3259654A1
(en)
|
2022-06-17 |
2023-12-21 |
Pfizer Inc. |
IL-12 VARIANTS, ANTI-PD1 ANTIBODIES, FUSING PROTEINS AND THEIR USES
|
|
GB202209518D0
(en)
|
2022-06-29 |
2022-08-10 |
Snipr Biome Aps |
Treating & preventing E coli infections
|
|
EP4626446A1
(en)
|
2022-12-01 |
2025-10-08 |
BioNTech SE |
Multispecific antibody against cd40 and cd137 in combination therapy with anti-pd1 ab and chemotherapy
|
|
IL321098A
(en)
|
2022-12-14 |
2025-07-01 |
Astellas Pharma Europe Bv |
Combination therapy including bispecific binding agents that bind to CLDN18.2- and CD3- and immune checkpoint inhibitors
|
|
IL321575A
(en)
|
2022-12-21 |
2025-08-01 |
Bristol Myers Squibb Co |
Combination therapy for lung cancer
|
|
JP2026504180A
(ja)
|
2023-01-30 |
2026-02-03 |
カイマブ・リミテッド |
抗体
|
|
WO2025032521A1
(en)
|
2023-08-10 |
2025-02-13 |
Pfizer Inc. |
Methods, therapies and uses for treating cancer
|
|
WO2025056180A1
(en)
|
2023-09-15 |
2025-03-20 |
BioNTech SE |
Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists
|
|
WO2025120866A1
(en)
|
2023-12-08 |
2025-06-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
|
|
TW202541837A
(zh)
|
2023-12-08 |
2025-11-01 |
日商安斯泰來製藥公司 |
含有結合至cldn18.2和cd3之雙特異性結合劑和穩定或增加cldn18.2表現之藥劑之組合療法
|
|
WO2025120867A1
(en)
|
2023-12-08 |
2025-06-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
|
|
WO2026033885A1
(en)
|
2024-08-08 |
2026-02-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
|
|
US20250215087A1
(en)
|
2023-12-29 |
2025-07-03 |
Bristol-Myers Squibb Company |
Combination therapy of kras inhibitor and treg depleting agent
|
|
US12521446B2
(en)
|
2024-02-27 |
2026-01-13 |
Bristol-Myers Squibb Company |
Anti-CEACAM5 antibody drug conjugates
|
|
WO2025184208A1
(en)
|
2024-02-27 |
2025-09-04 |
Bristol-Myers Squibb Company |
Anti-ceacam5 antibodies and uses thereof
|
|
WO2025245489A1
(en)
|
2024-05-24 |
2025-11-27 |
Bristol-Myers Squibb Company |
Treatment of tumors in subjects having fgl-1 positive samples
|
|
CN120405153B
(zh)
*
|
2025-07-04 |
2025-11-21 |
军科正源（北京）药物研究有限责任公司 |
双抗药物的中和抗体的检测方法
|